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1. INTRODUCTION {#cam42794-sec-0005}
===============

Biliary system is a tree‐like network of tubular structures, and could be classified into five segments according to the anatomic position, which are intrahepatic bile duct, hilar bile duct, gallbladder, distal bile duct, and ampulla of Vater from distal to proximal, respectively. Correspondingly, biliary tract cancer (BTC), originated from biliary system, have five subtypes, including intrahepatic cholangiocarcinoma (ICC), perihilar cholangiocarcinoma (PHCC), gallbladder cancer (GBC), distal cholangiocarcinoma (DCC), and carcinoma of Vater ampulla (AVC).[1](#cam42794-bib-0001){ref-type="ref"} BTC is a kind of uncommon but relatively aggressive malignancy and made up about 4% of malignant digestive system tumors, with a gradually increasing incidence in the past years.[2](#cam42794-bib-0002){ref-type="ref"}, [3](#cam42794-bib-0003){ref-type="ref"}

Complete surgical resection is the only curative treatment for BTC, but quite a few patients have no chance for radical surgery due to distant metastasis (DM) at initial diagnosis.[4](#cam42794-bib-0004){ref-type="ref"}, [5](#cam42794-bib-0005){ref-type="ref"} Although tremendous efforts have been made to explore the mechanisms of DM, the clinical features of DM in advanced BTC were poorly understood. Due to the low morbidity of BTC, the knowledge about the detailed DM mode mainly came from anatomy and clinical experience, and few clinical researches with large populations worked on it.[6](#cam42794-bib-0006){ref-type="ref"}, [7](#cam42794-bib-0007){ref-type="ref"}

Proper treatments are vital for advanced BTC patients. According to the NCCN clinical practice guideline of hepatobiliary cancers, palliative surgery was not encouraged owing to the high risk and the limited benefit, and chemotherapy and radiation were recommended. Even though great progress on the treatments has been made, the survival time and life quality were still frustrating.[8](#cam42794-bib-0008){ref-type="ref"} To understand the DM mode and therapy efficacy of the advanced BTC, we analyzed the metastasis sites of each cancer subtype and assessed the efficacy of different treatments in a large population.

2. METHOD {#cam42794-sec-0006}
=========

2.1. Patients and data collection {#cam42794-sec-0007}
---------------------------------

Eligible patients were enrolled from the Surveillance, Epidemiology, and End Results (SEER) database of the US National Cancer Institute. The TNM information of the SEER cohort was obtained based on the following codes: Derived AJCC Stage Group, 7th ed (7th edition; 2010‐2015), Derived AJCC T (7th edition; 2010‐2015), Derived AJCC N (7th edition; 2010‐2015), Derived AJCC M (7th edition; 2010‐2015), Derived SEER Cmb Stg Grp (2016+), Derived SEER Combined T (2016+), Derived SEER Combined N (2016+), Derived SEER Combined M (2016+). The DM site was classified into liver only, distant lymph node (dLN) only, lung only, brain only, bone only, multi‐metastasis, and others, based on SEER combined mets at DX‐bone (2010+), SEER combined mets at DX‐brain (2010+), SEER combined mets at DX‐liver (2010+), SEER combined mets at DX‐lung (2010+), CS mets at DX (2004‐2015), and mets at DX‐distant LN (2016+). In the 7th AJCC staging system, "intrahepatic metastasis" was defined as T2b disease in ICC; however, these cases were recorded as liver only metastasis in the SEER database inconsequently, and we had to conduct analysis according to the record of SEER database.

Inclusion criteria included: (a) patients diagnosed with BTC between 2010 and 2016; (b) accurate tumor stage classification according to the 7th AJCC staging system; and (c) complete available follow‐up information. Patients whose BTC were not the first and only malignant primary tumor or who were lost to follow‐up were excluded in the cohort 1. Note that patients who died within 2 months after initial diagnosis confirmed or received radiation or palliative surgery were excluded in the propensity score matching (PSM) process for less bias in the cohort 2.

The following clinicopathological variables were collected: clinic‐pathological factors (age at initial diagnosis, year at initial diagnosis, gender, race, tumor size, tumor differentiation, TNM stage, and metastasis site), economic factors (marital status, income, insurance, region, and residence city), and treatments (radiation, palliative surgery, and chemotherapy). Data regarding the detailed regimes of radiation, palliative surgery, and chemotherapy were unavailable. Survival duration was calculated from the date of initial diagnosis until the date of death or last follow‐up. The flow chart of inclusion and exclusion is shown in Figure [1](#cam42794-fig-0001){ref-type="fig"}.

![Flow chart of inclusion and exclusion in the study. The cohort 1 was for the analysis of distant metastasis mode and cox regression. The cohort 2 was for the survival analysis of chemotherapy efficacy and was built up by integrating the five subgroups. AVC, Carcinoma of Vater ampulla; BTC, biliary tract cancer DCC, Distal cholangiocarcinoma; GBC, Gallbladder cancer; ICC, Intrahepatic cholangiocarcinoma; PHCC, Perihilar cholangiocarcinoma; PS, Propensity score](CAM4-9-1335-g001){#cam42794-fig-0001}

2.2. Statistical analysis {#cam42794-sec-0008}
-------------------------

Continuous variables were analyzed by Student\'s *t* test, and categorical variables were calculated by Chi‐squared test. Survival duration was calculated by the median overall survival (OS), and survival curves were constructed using the Kaplan‐Meier method. Analyses were performed using MedCalc 15.2.2 (MedCalc Software bvba, Ostend, Belgium) and GraphPad Prism 8.0.0 (GraphPad Software, San Diego, California USA, <http://www.graphpad.com>). PSM process was performed by MatchIt package in R version 3.4.0 (Bell Laboratories, Murray Hill, NJ). A two‐sided P‐value less than 0.05 was considered statistically significant.

3. RESULTS {#cam42794-sec-0009}
==========

3.1. Baseline characteristics {#cam42794-sec-0010}
-----------------------------

Our study included 6348 BTC patients with DM (ICC: 1762, PHCC: 1103, GBC: 2580, DCC: 538, AVC: 365) who were diagnosed between 2010 and 2016. As depicted in Table [1](#cam42794-tbl-0001){ref-type="table"}, most of the factors appeared to differ significantly among the five subtypes except residence, which suggested enormous diversity inside the BTC.

###### 

Baseline characteristic of metastatic biliary tract cancer patients at initial diagnosis

  Factors              ICC, n (%)    PHCC, n (%)   GBC, n (%)    DCC, n (%)   AVC, n (%)   *P*          Total, n (%)
  -------------------- ------------- ------------- ------------- ------------ ------------ ------------ --------------
  Number of patients   1762          1103          2580          538          365                       6348
  Age, years                                                                                            
  ≤59                  573 (32.5)    280 (25.4)    625 (24.2)    127 (23.6)   89 (24.4)    **\<.001**   1694 (26.7)
  60‐69                577 (32.7)    364 (33.0)    751 (29.1)    184 (34.2)   99 (27.1)                 1975 (31.1)
  70‐79                417 (23.7)    287 (26.0)    688 (26.7)    133 (24.7)   103 (28.2)                1628 (25.6)
  ≥80                  195 (11.1)    172 (15.6)    516 (20.0)    94 (17.5)    74 (20.3)                 1051 (16.6)
  Sex                                                                                                   
  Male                 924 (52.4)    537 (48.7)    791 (30.7)    276 (51.3)   200 (54.8)   **\<.001**   2728 (43.0)
  Female               838 (47.6)    566 (51.3)    1789 (69.3)   262 (48.7)   165 (45.2)                3620 (57.0)
  Race                                                                                                  
  White                1359 (77.1)   842 (76.3)    1900 (73.6)   415 (77.1)   283 (77.5)   **\<.001**   4799 (75.6)
  Black                144 (8.2)     104 (9.4)     381 (14.8)    58 (10.8)    46 (12.6)                 733 (11.5)
  Others               259 (14.7)    157 (14.2)    299 (11.6)    65 (12.1)    36 (9.9)                  816 (12.9)
  Year at diagnosis                                                                                     
  2010‐1013            787 (44.7)    577 (52.3)    1417 (54.9)   293 (54.5)   203 (55.6)   **\<.001**   3277 (51.6)
  2014‐2016            975 (55.3)    526 (47.7)    1163 (45.1)   245 (45.5)   162 (44.4)                3071 (48.4)
  Marriage                                                                                              
  Yes                  1031 (58.5)   588 (53.1)    1290 (50.0)   290 (53.9)   190 (52.1)   **\<.001**   3389 (53.4)
  No                   731 (41.5)    515 (46.7)    1290 (50.0)   248 (46.1)   175 (47.9)                2959 (46.6)
  Income                                                                                                
  Low                  816 (46.3)    582 (52.8)    1327 (51.4)   289 (53.7)   187 (51.2)   **.001**     3201 (50.4)
  High                 946 (53.7)    521 (47.2)    1253 (48.6)   249 (46.3)   178 (48.8)                3147 (49.6)
  Insurance                                                                                             
  Yes                  1699 (96.4)   1043 (94.6)   2428 (94.1)   512 (95.2)   347 (95.1)   **.016**     6029 (95.0)
  No                   63 (3.6)      60 (5.4)      152 (5.9)     26 (4.8)     18 (4.9)                  319 (5.0)
  Region                                                                                                
  East                 632 (35.9)    350 (31.7)    966 (37.4)    222 (41.3)   122 (33.4)   **\<.001**   2292 (36.1)
  Pacific Coast        922 (52.3)    646 (58.6)    1265 (49.0)   241 (44.8)   200 (54.8)                3274 (51.6)
  Northern Plain       131 (7.4)     72 (6.5)      222 (8.6)     54 (10.0)    28 (7.7)                  507 (7.99)
  Alaska/Southwest     77 (4.4)      35 (3.2)      127 (4.9)     21 (3.9)     15 (4.1)                  275 (4.33)
  Residence city                                                                                        
  Small                262 (14.9)    158 (14.3)    404 (15.7)    107 (19.9)   57 (15.6)    .087         988 (15.6)
  Middle               391 (22.2)    257 (23.3)    527 (20.4)    113 (21.0)   73 (20.0)                 1361 (21.4)
  Large                1109 (62.9)   688 (62.4)    1649 (63.9)   318 (59.1)   235 (64.4)                3999 (63.0)
  Tumor size, mm                                                                                        
  ≤30                  115 (6.5)     165 (15.0)    394 (15.3)    118 (21.9)   123 (33.7)   **\<.001**   915 (14.4)
  30‐59                213 (12.1)    129 (11.7)    439 (17.0)    59 (11.00    61 (16.7)                 901 (14.2)
  \>60                 576 (32.7)    97 (8.8)      354 (13.7)    25 (4.6)     13 (3.6)                  1065 (16.8)
  Unknown              858 (48.7)    712 (64.5)    1393 (54.0)   336 (62.5)   168 (46.0)                3467 (54.6)
  Differentiation                                                                                       
  I‐II                 263 (14.9)    105 (9.5)     490 (19.0)    52 (9.7)     123 (33.7)   **\<.001**   1033 (16.3)
  III‐IV               277 (15.7)    135 (12.2)    686 (26.6)    75 (13.9)    103 (28.2)                1276 (20.1)
  Unknown              1222 (69.4)   863 (78.3)    1404 (54.4)   411 (76.4)   139 (38.1)                4039 (63.6)
  T stage                                                                                               
  T1‐T2                946 (53.7)    339 (30.7)    500 (19.4)    140 (26.0)   127 (34.8)   **\<.001**   2052 (32.3)
  T3‐T4                335 (19.0)    161 (14.6)    1340 (51.9)   183 (34.0)   140 (38.4)                2159 (34)
  TX                   481 (27.3)    603 (54.7)    740 (28.7)    215 (40.0)   98 (26.9)                 2137 (33.7)
  N stage                                                                                               
  N0                   739 (41.9)    468 (42.4)    1073 (41.6)   272 (50.6)   176 (48.2)   **.003**     2728 (43.0)
  N1                   693 (39.3)    412 (37.4)    1034 (40.1)   175 (32.5)   134 (36.7)                2448 (38.6)
  Nx                   330 (18.7)    223 (20.2)    473 (18.3)    91 (16.9)    55 (15.1)                 1172 (18.5)
  Metastasis site                                                                                       
  Bone only            109 (6.2)     24 (2.2)      39 (1.5)      12 (2.2)     4 (1.1)      **\<.001**   188 (3.0)
  Brain only           2 (0.1)       1 (0.1)       3 (0.1)       1 (0.2)      3 (0.8)                   10 (0.2)
  Liver only           344 (19.5)    481 (43.6)    1281 (49.7)   248 (46.1)   200 (54.8)                2554 (40.2)
  Lung only            159 (9.0)     51 (4.6)      79 (3.1)      31 (5.8)     33 (9.0)                  353 (5.6)
  dLN only             254 (14.4)    115 (10.4)    255 (9.9)     46 (8.6)     16 (4.4)                  686 (10.8)
  Other                288 (16.4)    158 (14.3)    463 (18.0)    96 (17.8)    54 (14.8)                 1059 (16.7)
  Multi‐metastasis     606 (34.4)    273 (24.8)    460 (17.8)    104 (19.3)   55 (15.1)                 1498 (23.6)
  Radiation                                                                                             
  Yes                  193 (11.0)    89 (8.1)      193 (7.5)     46 (8.6)     29 (7.9)     **.002**     550 (8.7)
  No                   1569 (89.0)   1014 (91.9)   2387 (92.5)   492 (91.4)   336 (92.1)                5798 (91.3)
  Palliative surgery                                                                                    
  Yes                  71 (4.0)      50 (4.5)      858 (33.3)    43 (8.0)     50 (13.7)    **\<.001**   1072 (16.9)
  No                   1691 (96.0)   1053 (95.5)   1722 (66.7)   495 (92.1)   315 (86.3)                5276 (83.1)
  Chemotherapy                                                                                          
  Yes                  1049 (59.5)   527 (47.8)    1283 (49.7)   261 (48.5)   212 (58.1)   **\<.001**   3332 (52.5)
  No                   713 (40.5)    576 (52.2)    1297 (50.3)   277 (51.5)   153 (41.9)                3016 (47.5)

*P* \< .05 is considered statistically significant (bold).

Abbreviation: AVC, Carcinoma of Vater ampulla; dLN, Distant lymph node; DCC, Distal cholangiocarcinoma; GBC, Gallbladder cancer; ICC, Intrahepatic cholangiocarcinoma; PHCC, Perihilar cholangiocarcinoma.

John Wiley & Sons, Ltd

3.2. Distant metastasis mode {#cam42794-sec-0011}
----------------------------

DM mode was an important form of the diversity. As shown in Figure [2](#cam42794-fig-0002){ref-type="fig"}A, the proportion of M1 patients in each subtype at first diagnosis was 26.4% in the ICC, 37.2% in the PHCC, 41. 0% in the GBC, 24.5% in the DCC, and 12.7% in the AVC, respectively. The GBC had the highest DM rate and the highest liver only rate (22.1%), which meant that more than 2/5 of the GBC patients had the DM, and over half of them were the liver only DM. The DM rate and the liver only rate of the PHCC were slightly less than that in the GBC, while its multi‐metastasis rate was the highest. Although the ICC and the DCC had similar DM rate (more than 1/3), the most common DM site of the ICC and the DCC were the multi‐metastasis (9.1%) and the liver only (11.3%), respectively. Conversely, only less than 1/5 of the M1 ICC patients had the liver only DM, and nearly half of the M1 DCC patients had the liver only DM. More than 1/3 of the M1 DCC patients had the multi‐metastasis, while only 1/6 of the M1 ICC patients had the multi‐metastasis. The AVC had the lowest DM rate (12.7%), and nearly half of them were liver only DM.

![Distant metastasis mode of each subtype of the BTC. A, proportion of the M1 patients at first diagnosis in each subtype. B, Venn diagrams of the distribution of distant metastatic sites in each subtype. BTC, biliary tract cancer; ICC, Intrahepatic cholangiocarcinoma; PHCC, Perihilar cholangiocarcinoma; GBC, Gallbladder cancer; DCC, Distal cholangiocarcinoma; AVC, Carcinoma of Vater ampulla; dLN, Distant lymph node](CAM4-9-1335-g002){#cam42794-fig-0002}

As other metastasis sites, the dLN only was commonly seen in the ICC (3.8%), the PHCC (3.9%), and the GBC (4.4%); the bone only was mostly found in the ICC (1.6%); the lung only rate was similar in all the subtypes (1.2%‐2.4%), and the brain only was extremely rare in all the subtypes (all ≤0.1%). In addition, there were still part of patients without accurate record of the metastasis sites in all the subtypes.

The multi‐metastasis could be found in some patients at initial diagnosis. The most common combination was liver plus lung, and the second one was liver plus dLN. This was in accord with the fact that liver, dLN, and lung were the top three DM sites in most of the BTC (Figure[2](#cam42794-fig-0002){ref-type="fig"}B and Figure [S2‐S7](#cam42794-sup-0001){ref-type="supplementary-material"}), indicating that the combinations of the multi‐metastasis were closely related to the DM rate of a single site. However, although the rate of liver plus lung was higher than that of liver plus dLN (liver plus lung rate vs liver plus dLN rate: ICC, 7.1% vs 6.2%; PHCC, 7.8% vs 4.6%; GBC, 5.0% vs 4.6%; DCC, 5.8% vs 4.7%; AVC, 4.9% vs 3.3%), the dLN DM rate was higher than the lung DM rate in most of the BTC (dLN vs lung: ICC, 14.4% vs 9.0%; PHCC, 10.4% vs 4.6%; GBC, 9.9% vs 3.1%; DCC, 8.6% vs 5.8%; AVC, 4.4% vs 9.0%) (Figure [2](#cam42794-fig-0002){ref-type="fig"}B, Figure [S2‐S7](#cam42794-sup-0001){ref-type="supplementary-material"}), suggesting that the multi‐site metastasis might be progressed step by step but not randomly combined. All the specific combinations of different sites are shown in Figure [2](#cam42794-fig-0002){ref-type="fig"}B, and more detailed information about metastasis mode is shown in Figure [S2‐S7](#cam42794-sup-0001){ref-type="supplementary-material"}.

Although all the M1 BTC patients shared a compromised prognosis, survival of different metastasis sites displayed significantly different (*P* \< .001 in the ICC, *P* = .005 in the PHCC, *P* \< .001 in the GBC, *P* = .011 in the DCC, and *P* \< .001 in the AVC, respectively) (Figure [3](#cam42794-fig-0003){ref-type="fig"}). In our survival analysis, multi‐metastasis always indicated a shortest survival, while dLN only always indicated a better prognosis. Moreover, the bone only in the ICC, GBC, and DCC, the lung only in the PHCC, and the liver only in the GBC were also poor predictors for OS. The brain only was excluded in this analysis for the insufficient patient numbers.

![Kaplan--Meier curves of overall survival according to metastasis sites in the total cohort and each subtype. AVC, Carcinoma of Vater ampulla; BTC, biliary tract cancer; DCC, Distal cholangiocarcinoma; dLN, Distant lymph node; GBC, Gallbladder cancer; ICC, Intrahepatic cholangiocarcinoma; PHCC, Perihilar cholangiocarcinoma](CAM4-9-1335-g003){#cam42794-fig-0003}

3.3. Univariate and multivariate cox analysis {#cam42794-sec-0012}
---------------------------------------------

Univariate and multivariate cox analysis were conducted to further identify the potential factors that might influence survival besides metastasis sites. In the univariate cox analysis, age, race, marital status, insurance, tumor size, differentiation, T stage, N stage, metastasis sites, and treatments (radiation, palliative surgery, and chemotherapy) were identified to be significantly associated with OS in at least two subtypes (Table [S1](#cam42794-sup-0001){ref-type="supplementary-material"}). Besides, sex in the ICC, and year at diagnosis and residence in the GBC were also significant predictors.

These factors proved to be significant predictors above were then entered into the multivariate cox proportional hazards model of different subtypes separately. As shown in Table [2](#cam42794-tbl-0002){ref-type="table"}, the independent prognostic indicators were demonstrated in the ICC (age, sex, differentiation, metastasis site, radiation, palliative surgery, and chemotherapy), the PHCC (age, race, region, tumor size, metastasis site, palliative surgery, and chemotherapy), the GBC (age, income, tumor size, differentiation, N stage, metastasis site, palliative surgery, and chemotherapy), the DCC (palliative surgery and chemotherapy), and the AVC(differentiation, metastasis site, palliative surgery, and chemotherapy). Based on the results, the clinic‐pathological factors (age, race, sex, differentiation, tumor size, and metastasis site) and the treatments (palliative surgery and chemotherapy) play important roles in patient survival, while the economic factors\' (region and income) influence was rather limited. Interestingly, T stage and N stage also only had limited influence. Furthermore, factors identified above in the ICC, PHCC, and GBC were more abundant compared with that in the DCC and the AVC, where the treatments had the most significant influence in patient prognosis.

###### 

Multivariate cox regression models of prognostic factors for overall survival

  Factors                    ICC (n = 1762)         PHCC (n = 1103)   GBC (n = 2580)         DBDC (n = 538)   AVC (n = 365)                                                                                 
  -------------------------- ---------------------- ----------------- ---------------------- ---------------- --------------------- ------------ ---------------------- ------------ ---------------------- ------------
  Age, years                                                                                                                                                                                                
  60‐69 vs ≤ 59              1.143 (1.004‐1.302)    **.045**          1.268 (1.071‐1.502)    **.006**         1.091 (0.971‐1.226)   0.147        0.906 (0.704‐ 1.165)   .443         0.868 (0.618‐1.218)    .415
  70‐79 vs ≤ 59              1.270 (1.099‐1.466)    **.001**          1.374 (1.146‐1.647)    **\<.001**       1.177 (1.044‐1.326)   **.008**     1.258 (0.963‐1.645)    .095         1.152 (0.826‐1.607)    .406
  ≥80 vs ≤ 59                1.410 (1.168‐1.703)    **\<.001**        1.226 (0.991‐1.517)    .063             1.422 (1.246‐1.622)   **\<.001**   1.299 (0.961‐1.755)    .091         0.974 (0.662‐1.432)    .892
  Sex                                                                                                                                                                                                       
  Male vs Female             0.772 (0.694‐0.858)    **\<.001**                                                                                                                                               
  Race                                                                                                                                                                                                      
  Black vs White                                                      0.919 (0.738‐1.145)    .456                                                1.105 (0.818‐1.492)    .517                                 
  Others vs White                                                     0.661 (0.546‐0.802)    **\<.001**                                          0.846 (0.630‐1.136)    .268                                 
  Year at diagnosis                                                                                                                                                                                         
  14‐16 vs 10‐13                                                                                              0.958 (0.878‐1.045)   .334                                                                     
  Marriage                                                                                                                                                                                                  
  Yes vs No                  1.106 (0.993‐1.233)    .069                                                      1.054 (0.967‐1.149)   .237         1.179 (0.977‐1.423)    .088                                 
  Income                                                                                                                                                                                                    
  Low vs High                                                                                                 1.155 (1.062‐1.256)   **\<.001**                                                               
  Insurance                                                                                                                                                                                                 
  No vs Yes                  1.001 (0.759‐1.322)    .993                                                      0.949 (0.793‐1.135)   .566                                                                     
  Region                                                                                                                                                                                                    
  Pacific Coast vs East      1.142 (0.934‐1.396)    .197              0.724 (0.555‐0.943)    **.016**                                                                                                        
  Northern Plain vs East     0.972 (0.868‐1.089)    .629              0.908 (0.786‐1.049)    .193                                                                                                            
  Alaska/Southwest vs East   0.910 (0.701‐1.183)    .484              0.926 (0.632‐1.338)    .663                                                                                                            
  Residence city                                                                                                                                                                                            
  Middle vs Large                                                                                             1.018 (0.915‐1.132)   .745                                                                     
  Small vs Large                                                                                              1.136 (0.947‐1.209)   .281                                                                     
  Tumor size, mm                                                                                                                                                                                            
  30‐59 vs ≤ 29              0.871 (0.672‐1.128)    .298              1.104 (0.863‐1.412)    .435             1.115 (0.967‐1.149)   .168         1.155 (0.822‐1.622)    .410                                 
  \>60 vs ≤ 29               0.985 (0.783‐1.240)    .899              1.363 (1.037‐1.791)    **.017**         1.243 (1.056‐1.462)   **.009**     1.010 (0.621‐1.642)    .969                                 
  Unknown vs ≤ 29            1.023 (0.815‐1.285)    .844              1.252 (1.042‐1.504)    **.017**         1.276 (1.119‐1.456)   **\<.001**   1.099 (0.862‐1.401)    .449                                 
  Differentiation                                                                                                                                                                                           
  III/ IV vs I‐II            1.312 (1.085‐1.588)    **.005**                                                  1.460 (1.282‐1.663)   **\<.001**   1.167 (0.778‐1.749)    .458         1.816 (1.333‐2.474)    **\<.001**
  Unknown vs I‐II            1.373 (1.178‐1.601)    **\<.001**                                                1.242 (1.081‐1.426)   **.002**     1.137 (0.803‐1.609)    .471         1.122 (0.849‐1.484)    .421
  T stage                                                                                                                                                                                                   
  T3‐T4 vs T1‐T2             0.948 (0.825‐1.089)    .448                                                      0.955 (0.849‐1.075)   .447                                                                     
  TX vs T1‐T2                0.905 (0.790‐1.037)    .154                                                      0.940 (0.812‐1.087)   .406                                                                     
  N stage                                                                                                                                                                                                   
  N1 vs N0                                                            1.001 (0.860‐1.165)    .990             1.024 (0.928‐1.130)   .635                                                                     
  Nx vs N0                                                            1.169 (0.984‐1.389)    .107             1.129 (1.001‐1.273)   **.049**                                                                 
  Metastasis site                                                                                                                                                                                           
  Liver vs DLN               0.970 (0.803‐1.171)    .751              1.243 (0.986‐ 1.569)   .068             1.348 (1.153‐1.575)   **\<.001**   0.968 (0.680‐1.378)    .856         0.840 (0.452‐1.559)    .582
  Lung vs DLN                1.113 (0.895‐1.383)    .338              1.346 (0.950‐1.908)    .097             1.022 (0.771‐1.355)   .882         1.047 (0.635‐1.725)    .859         0.789 (0.388‐1.606)    .515
  Brain vs DLN               3.075 (0.761‐12.434)   .117              2.027 (0.274‐14.979)   .491             1.419 (0.453‐4.447)   .551         5.244 (0.710‐38.728)   .106         2.127 (0.578‐7.833)    .259
  Bone vs DLN                1.323 (1.030‐1.700)    **.029**          1.089 (0.673‐1.762)    .731             1.901 (1.306‐2.766)   **\<.001**   1.594 (0.811‐3.133)    .178         3.499 (1.096‐11.167)   **.035**
  Others vs DLN              1.079 (0.894‐1.303)    .432              1.121 (0.859‐1.463)    .403             1.307 (1.097‐1.558)   **\<.001**   0.801 (0.539‐1.190)    .274         0.934 (0.473‐1.844)    .844
  Multi vs DLN               1.332 (1.126‐1.576)    **\<.001**        1.612 (1.266‐2.053)    **\<.001**       1.470 (1.236‐1.748)   **\<.001**   1.204 (0.820‐1.768)    .346         1.683 (0.869‐3.260)    .125
  Radiation                                                                                                                                                                                                 
  Yes vs No                  0.750 (0.631‐0.891)    **.001**          0.895 (0.704‐1.138)    .368             0.950 (0.804‐1.123)   .553                                                                     
  Palliative surgery                                                                                                                                                                                        
  Yes vs No                  0.528 (0.398‐0.699)    **\<.001**        0.402 (0.290‐0.558)    **\<.001**       0.636 (0.561‐0.720)   **\<.001**   0.452 (0.286‐0.714)    **\<.001**   0.356 (0.237‐0.534)    **\<.001**
  Chemotherapy                                                                                                                                                                                              
  Yes vs No                  0.274 (0.243‐0.310)    **\<.001**        0.381 (0.330‐0.438)    **\<.001**       0.403 (0.367‐0.443)   **\<.001**   0.350 (0.285‐0.429)    **\<.001**   0.309 (0.234‐0.409)    **\<.001**

*P*\<0.05 is considered statistically significant (bold).

Abbreviations:AVC, Carcinoma of Vater ampulla; CI, Confidence interval; dLN, Distant lymph node; GBC, Gallbladder cancer; DCC, Distal cholangiocarcinoma; HR, Hazard ratio; ICC, Intrahepatic cholangiocarcinoma; PHCC, Perihilar cholangiocarcinoma.
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3.4. Chemotherapy efficacy in different BTC subtypes {#cam42794-sec-0013}
----------------------------------------------------

Treatments for the M1 BTC patients included radiation, palliative surgery, and chemotherapy. Radiation only worked in the ICC with a higher hazard ratio (HR) than chemotherapy (Table [2](#cam42794-tbl-0002){ref-type="table"}), and palliative surgery was always considered harmful in the NCCN clinical practice guideline of hepatobiliary cancers, and only very few patients received it (Table [1](#cam42794-tbl-0001){ref-type="table"}). Chemotherapy was the main choice at present, and it proved to be a significant method to prolong patient survival in multivariate cox model (yes vs no: ICC, HR (95%CI): 0.274 (0.243‐0.310), *P* \< .001; PHCC, HR (95%CI): 0.381 (0.330‐0.438), *P* \< .001; GBC, HR (95%CI): 0.403 (0.367‐0.443), *P* \< .001; DCC, (95%CI): 0.350 (0.285‐0.429), *P* \< .001; AVC, HR (95%CI), 0.309 (0.234‐0.409), *P* \< .001).

To further assess the therapeutic value of chemotherapy, Kaplan‐Meier survival analysis was adopted and median survival was calculated simultaneously. Patients lived less than 2 months or received radiation or palliative surgery were excluded in this analysis to reduce possible bias between chemotherapy group and no chemotherapy group. However, significant difference of baseline characteristics existed between two groups in the total cohort (Table [3](#cam42794-tbl-0003){ref-type="table"}) and all the subtypes (Table [S2‐S6](#cam42794-sup-0001){ref-type="supplementary-material"}). PSM was conducted to correct bias in each subtype separately with an appropriate caliper of 0.04, and then all the baseline characteristics between two groups presented no difference in the five subtypes (Table [S2‐S6](#cam42794-sup-0001){ref-type="supplementary-material"}). The total cohort was integrated from the five subtypes (Table [3](#cam42794-tbl-0003){ref-type="table"}).

###### 

Baseline characteristics of the without (No) and with chemotherapy (Yes) groups before and after PSM

  Factors             Before PSM   After PSM                            
  ------------------- ------------ ----------- ------------ ----- ----- -------
  Location                                                              
  ICC                 155          682         **\<.001**   141   141   1.000
  PHCC                145          356                      122   122    
  GBC                 197          567                      167   167    
  DCC                 79           165                      55    55     
  AVC                 55           136                      31    31     
  Age, years                                                            
  ≤59                 132          675         **\<.001**   125   112   .499
  60‐69               163          655                      154   169    
  70‐79               159          451                      136   167    
  ≥80                 177          125                      101   68     
  Sex                                                                   
  Male                262          856         .149         226   240   .416
  Female              369          1050                     290   276    
  Race                                                                  
  White               455          1453        **.011**     379   379   .669
  Black               72           219                      58    68     
  Others              104          234                      79    69     
  Year at diagnosis                                                     
  2010‐1013           361          994         **.031**     293   286   .707
  2014‐2016           270          912                      223   230    
  Marriage                                                              
  Yes                 266          1172        **\<.001**   246   259   .455
  No                  365          734                      270   257    
  Income                                                                
  Low income          308          990         0.187        255   256   1.000
  High income         323          916                      261   260    
  Insurance                                                             
  Yes                 594          1851        **\<.001**   17    25    .271
  No                  37           55                       499   491    
  Region                                                                
  East                190          738         **\<.001**   165   195   .209
  Pacific Coast       48           152                      35    36     
  Northern Plain      365          946                      293   268    
  Alaska/Southwest    28           70                       23    17     
  Residence city                                                        
  Small               420          1214        .327         348   320   .168
  Middle              129          403                      102   114    
  Large               82           289                      66    82     
  Tumor size, mm                                                        
  ≤30                 90           247         .602         72    77    .912
  30‐59               93           272                      76    67     
  \>60                75           369                      69    76     
  Unknown             373          1018                     299   296    
  Differentiation                                                       
  I‐II                92           271         .474         74    65    .965
  III‐IV              76           289                      59    78     
  Unknown             463          1346                     383   373    
  T stage                                                               
  T1‐T2               186          661         **.001**     157   158   .981
  T3‐T4               183          595                      154   156    
  TX                  262          650                      205   202    
  N stage                                                               
  N0                  284          786         .336         238   229   .839
  N1                  199          807                      168   191    
  Nx                  148          313                      110   96     
  Metastasis site                                                       
  dLN only            68           243         **\<.001**   56    68    .515
  Liver only          294          677                      227   217    
  Lung only           44           132                      33    26     
  Brain only          2            0                        2     0      
  Bone only           15           37                       13    5      
  Other               115          305                      100   80     
  Multi‐metastasis    93           512                      85    120    

*P* \< .05 is considered statistically (bold).

Abbreviations: AVC, Carcinoma of Vater ampulla; dLN, Distant lymph node; DBDC, Distal cholangiocarcinoma; GBC, Gallbladder cancer; ICC, Intrahepatic cholangiocarcinoma; PHCC, Perihilar cholangiocarcinoma.
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Survival analysis was carried out subsequently, and the results are presented in Figure [4](#cam42794-fig-0004){ref-type="fig"}. In the total cohort, chemotherapy was significantly associated with improved survival months (chemotherapy vs no‐chemotherapy: 8, 95%CI: 8‐9 vs 5, 95%CI: 5‐6 for median OS) (*P* \< .001). The improvement on OS after receiving chemotherapy also existed in each subtype (all *P* \< .001); however, the level of survival improvement manifested different among the subtypes. The median OS for the ICC, PHCC, and AVC were elevated from 5 months to 9 months, from 6 months to 10 months, and from 4 months to 9 months after receiving chemotherapy, respectively. While, the elevation of survival time for the GBC and the DCC was only from 6 months to 7 months and from 6 months to 8 months, respectively, demonstrating insufficient efficacy of current chemotherapy regimens for the GBC and the DCC.

![Kaplan‐Meier curves of overall survival according to whether or not receiving chemotherapy in each subtype of the BTC. AVC, Carcinoma of Vater ampulla; DCC, Distal cholangiocarcinoma; GBC, Gallbladder cancer; ICC, Intrahepatic cholangiocarcinoma; PHCC, Perihilar cholangiocarcinoma](CAM4-9-1335-g004){#cam42794-fig-0004}

4. DISCUSSION {#cam42794-sec-0014}
=============

Correct understanding for the DM mode of the advanced BTC is helpful for accurate diagnosis and optimal treatment selection. Meanwhile, in consideration of the fact that clinical researches about treatment strategies in the BTC always included multiple subtypes, a valid and credible evaluation to the efficacy of current therapy in each subtype is urgently needed. In this study, we described the DM modes of the BTC in a large population, revealed the survival differences among DM sites, and found the different efficacy of current treatments in each subtype.

The DM mode of each subtype was apparently unique. Although liver only and dLN only were the top two metastasis sites in all the subtypes, DM rates of these subtypes extremely varied, ranging from 12.7% to 41.0%, and the proportions of the metastasis sites differed distinctively. About the differences of DM modes, there were some theoretical bases in clinical features and anatomy. Obstructive jaundice might develop at an early stage in the DCC and the AVC, while the GBC and the PHCC are always symptom‐free or just manifested by some nonspecific symptoms, such as sour regurgitation, nausea, and abdominal pain.[9](#cam42794-bib-0009){ref-type="ref"} Pathological difference might be an important factor, because the GBC and the PHCC are always more malignant and have a higher recurrence rate and a higher mortality rate after resection. Adjacency to visceral organ and complex vascular lymphatic system might also play an important role. The underlying mechanism is complicated and requires further investigations.

Despite the poor prognosis of the advanced BTC in whole, these metastasis sites still manifested different survival. Multi‐metastasis always indicated the shortest survival in our study, and dLN only always indicated a better prognosis, which might suggest the different disease progression, although they were both in M1 stage. Also, some metastasis sites showed different survival among the subtypes, which indicated the peculiarity of the DM mode of each subtype. Besides metastasis sites, there were some other clinic‐pathological factors, economic factors, and treatments relating to the patient survival. Most of the factors have been proved to influence the prognosis of the resectable BTC patients before, such as marital status, differentiation, and treatment, but the influence of T stage and N stage in the advanced BTC was fairly limited and not clearly as that in resectable cases.[10](#cam42794-bib-0010){ref-type="ref"}, [11](#cam42794-bib-0011){ref-type="ref"}, [12](#cam42794-bib-0012){ref-type="ref"} Interestingly, there is no factor having a significant survival effect in all the five subtypes except treatments. Choosing a proper treatment seemed the only thing that we could do for the advanced BTC patients, and a valid and credible evaluation to the efficacy of different therapies is of great value.

Radiation and palliative surgery did not work in the BTC according to our study, the previous researches, and the NCCN guideline.[13](#cam42794-bib-0013){ref-type="ref"} The remaining choice for M1 BTC patients was chemotherapy. As the gold standard, GemCis regimen (gemcitabine‐cisplatin) could elevate the median survival of the unresectable BTC patients from 8.1 to 11.7 months compared with gemcitabine monotherapy and did not reduce the quality of life.[14](#cam42794-bib-0014){ref-type="ref"}, [15](#cam42794-bib-0015){ref-type="ref"} A similar magnitude of benefit from the GemCis regimen was seen in the BT‐22 study.[16](#cam42794-bib-0016){ref-type="ref"} Besides, the GEMOX (gemcitabine‐oxaliplatin) also proved to be active and well tolerated in the unresectable BTC.[17](#cam42794-bib-0017){ref-type="ref"} However, these clinical researches included all the subtypes regardless of the different pathological basis, which severely limited the clinical application. In spite of the unavailability of the detailed regimes of chemotherapy in our study, improvement on survival after receiving chemotherapy also existed in each subtype. However, the level of survival improvement manifested different among the subtypes. In the PSM analysis, the median OS of patients receiving chemotherapy was nearly two times longer than those not receiving chemotherapy in the ICC, PHCC, and AVC, but the elevation of survival time for the GBC and the DCC was no more than 2 months. In view of the insufficient efficacy of chemotherapy, the role of targeted therapy and the immunotherapy needs further study. Targeted therapy and the immunotherapy showed effective results in some cancers, but the effect of them on the advanced BTC is still obscure. The effect of the EGFR inhibitors, the HER‐2 inhibitors, and the VEGF inhibitors did not demonstrate a better prognosis compared with GEMOX regimen, but part of patients could get a complete or partial remission.[18](#cam42794-bib-0018){ref-type="ref"}, [19](#cam42794-bib-0019){ref-type="ref"}, [20](#cam42794-bib-0020){ref-type="ref"}, [21](#cam42794-bib-0021){ref-type="ref"}, [22](#cam42794-bib-0022){ref-type="ref"} Immunotherapy might be a promising treatment for the advanced BTC because the expression of PD‐1/PD‐L1 elevated in the BTC tissue. Further researches are being carried out all over the world.[23](#cam42794-bib-0023){ref-type="ref"}, [24](#cam42794-bib-0024){ref-type="ref"}

This study has some inevitable limitations primarily caused by the nature of the SEER database. First, the study was limited by its retrospective nature. It is necessary to validate our results in a prospective study or another large‐volume database. Second, there were still potential bias caused by the lack of some clinical characteristics, including palliative surgical procedures and the data regarding the detailed regimes of chemotherapy and radiation. Third, subgroup analyses for the chemotherapy efficacy of different metastasis sites in each subtype were not conducted for the insufficient patient numbers. At last, the record of peritoneal carcinomatosis was unavailable in SEER database, which is one of the common metastatic sites by BTC. Given these limitations, more efforts should be undertaken to validate our conclusion prior to clinical application.

5. CONCLUSION {#cam42794-sec-0015}
=============

In conclusion, we provided a detailed landscape of the DM mode of the advanced BTC in a large population, found the survival differences among DM sites, and revealed the different chemotherapy efficacy of the BTC subtypes.
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